Arnold Library

Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Brasky, Theodore M and Bonner, Matthew R and Moysich, Kirsten B and Ambrosone, Christine B and Nie, Jing and Tao, Meng Hua and Edge, Stephen B and Kallakury, Bhaskar V S and Marian, Catalin and Goerlitz, David S and Trevisan, Maurizio and Shields, Peter G and Freudenheim, Jo L (2011) Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer causes & control : CCC, 22 (7). pp. 965-75. ISSN 1573-7225

[thumbnail of Complete manuscript]
Preview
Text (Complete manuscript)
BraskyTM_NSAIDs_Breast_Cancer_Molecular_Subtypes.pdf
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (165kB) | Preview
Article URL: http://www.springerlink.com/content/16836855063362...

Abstract

Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of breast cancer, though findings have been inconsistent. This inconsistency may result from differences in etiology for breast tumors of different subtypes. We examined the association between NSAID use and breast cancer characterized by molecular subtypes in a population-based case-control study in Western New York. Cases (n = 1,170) were women with incident, primary, histologically confirmed breast cancer. Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (≥ 65 years). Participants answered questions regarding their use of aspirin and ibuprofen in the year prior to interview and their use of aspirin throughout their adult life. Logistic regression models estimated odds ratios (OR) and 95% confidence intervals (95% CI). Recent and lifetime aspirin use was associated with reduced risk, with no differences by subtype. Recent use of ibuprofen was significantly associated with increased risk of ER+/PR+(OR 1.33, 95% CI: 1.09-1.62), HER2- (OR 1.27, 95% CI: 1.05-1.53), and p53- breast cancers (OR 1.28, 95% CI: 1.04-1.57), as well as luminal A or B breast cancers. These findings support the hypothesis of heterogeneous etiologies of breast cancer subtypes and that aspirin and ibuprofen vary in their effects.

Item Type: Article or Abstract
Additional Information: The final publication is available at www.springerlink.com
DOI: 10.1007/s10552-011-9769-9
PubMed ID: 21516318
NIHMSID: NIHMS322178
PMCID: PMC3178267
Grant Numbers: DAMD-17-03-1-0446, DAMD-17-96-1-6202, R01-CA92040, P50-AA09802, R25- CA94880, K05-CA154337
Depositing User: Library Staff
Date Deposited: 01 Sep 2011 23:44
Last Modified: 16 Sep 2015 07:17
URI: http://authors.fhcrc.org/id/eprint/496

Repository Administrators Only

View Item View Item